Long-term suppression of luteinizing hormone, follicle-stimulating hormone and testosterone by daily administration of leuprolide.

Glode LM; Smith JA Jr

doi:10.1016/s0022-5347(17)43870-5

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Coronavirus articles and preprints
Search examples: "breast cancer" Smith J

Long-term suppression of luteinizing hormone, follicle-stimulating hormone and testosterone by daily administration of leuprolide.

Glode LM,

Smith JA Jr

The Journal of Urology, 01 Jan 1987, 137(1):57-60
DOI: 10.1016/s0022-5347(17)43870-5 PMID: 3098990

Abstract

The chronic effect of long-term injections of leuprolide on the hypothalamic, pituitary and gonadal axes have been studied in men with advanced prostatic cancer. The possibility of transient acute changes in luteinizing hormone, follicle-stimulating hormone and testosterone after each daily injection was studied in 31 patients treated for more than 1 year. No evidence of escape from daily 1.0 mg. doses was noted. No pituitary responsiveness was observed at any time point examined. Thus, daily administration of 1.0 mg. leuprolide acetate subcutaneously produces durable, complete suppression of gonadotropins and testosterone for prolonged periods.

Full text links

Read article at publisher's site (DOI): 10.1016/s0022-5347(17)43870-5

References

Articles referenced by this article (20)

Gonadotropin-releasing hormone: molecular and cell biology, physiology, and clinical applications.
Conn PM, Hsueh AJ, Crowley WF Jr
Fed Proc, (9):2351-2361 1984
MED: 6327393
Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence.
Matsuo H, Baba Y, Nair RM, Arimura A, Schally AV
Biochem Biophys Res Commun, (6):1334-1339 1971
MED: 4936338
Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones.
Schally AV, Arimura A, Kastin AJ, Matsuo H, Baba Y, Redding TW, Nair RM, Debeljuk L, White WF
Science, (4001):1036-1038 1971
MED: 4938639
Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms.
Ahmed SR, Brooman PJ, Shalet SM, Howell A, Blacklock NJ, Rickards D
Lancet, (8347):415-419 1983
MED: 6135909
Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.
Faure N, Lemay A, Laroche B, Robert G, Plante R, Jean C, Thabet M, Roy R, Fazekas AT
Prostate, (6):601-624 1983
MED: 6415632
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens.
Labrie F, Dupont A, Belanger A, Lacoursiere Y, Raynaud JP, Husson JM, Gareau J, Fazekas AT, Sandow J, Monfette G
Prostate, (6):579-594 1983
MED: 6415630
Treatment of prostatic cancer with LH-RH analogues.
Borgmann V, Nagel R, Al-Abadi H, Schmidt-Gollwitzer M
Prostate, (6):553-568 1983
MED: 6415628
Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma.
Koutsilieris M, Tolis G
Prostate, (6):569-577 1983
MED: 6415629
Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer.
Klijn JG, de Jong FH
Lancet, (8283):1213-1216 1982
MED: 6122975
Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report.
Comite F, Cutler GB Jr, Rivier J, Vale WW, Loriaux DL, Crowley WF Jr
N Engl J Med, (26):1546-1550 1981
MED: 6458765

Show 10 more references (10 of 20)

Citations & impact

Impact metrics

Citations

Jump to Citations

Citations of article over time

Smart citations by scite.ai
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1016/s0022-5347(17)43870-5

Supporting

Mentioning

Contrasting

Article citations

Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy.
Beer TM, Garzotto M, Eilers KM, Lemmon D
J Urol, 169(5):1738-1741, 01 May 2003
Cited by: 18 articles | PMID: 12686821
Hormonal therapy for stage D cancer of the prostate.
Gudziak MR, Smith AY
West J Med, 160(4):351-359, 01 Apr 1994
Cited by: 6 articles | PMID: 8023485 | PMCID: PMC1022427
Review Free to read
Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer.
Montie JE, Pienta KJ
Urology, 43(6):892-899, 01 Jun 1994
Cited by: 55 articles | PMID: 7515207
Review
Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
Plosker GL, Brogden RN
Drugs, 48(6):930-967, 01 Dec 1994
Cited by: 66 articles | PMID: 7533699
Review
A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Tyrrell CJ, Altwein JE, Klippel F, Varenhorst E, Lunglmayr G, Boccardo F, Holdaway IM, Haefliger JM, Jordaan JP
J Urol, 146(5):1321-1326, 01 Nov 1991
Cited by: 56 articles | PMID: 1834864

Go to all (9) article citations

Search worldwide, life-sciences literature

Long-term suppression of luteinizing hormone, follicle-stimulating hormone and testosterone by daily administration of leuprolide.

Abstract

Full text links

References

Gonadotropin-releasing hormone: molecular and cell biology, physiology, and clinical applications.

Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence.

Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones.

Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms.

Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.

New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens.

Treatment of prostatic cancer with LH-RH analogues.

Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma.

Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer.

Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report.

Citations & impact

Impact metrics

Citations of article over time

Smart citations by scite.ai
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1016/s0022-5347(17)43870-5

Article citations

Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy.

Hormonal therapy for stage D cancer of the prostate.

Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer.

Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.

Similar Articles

Endocrine and clinical effects of leuprolide in prostatic cancer.

Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.

A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer.

Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.

Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.

Similar Articles

Endocrine and clinical effects of leuprolide in prostatic cancer.
Clin Pharmacol Ther, 36(3):350-354, 01 Sep 1984

Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
Urology, 25(2):106-114, 01 Feb 1985

A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer.
BJU Int, 103 Suppl 2:7-13, 01 Mar 2009

Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
Drugs Exp Clin Res, 15(8):373-387, 01 Jan 1989

Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.